Type 1 Diabetes Clinical Trial
Official title:
A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes
A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the
insulin production in patients with new onset Type 1 diabetes.
Kineret® is already being used in the treatment of patients suffering from rheumatoid
arthritis and preclinical studies are now suggesting that it may also be useful for patients
with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist,
a blocker of an immune-signal molecule named interleukin-1.
The trial is a blinded randomised trial, in which the patient is allocated to receive the
active drug (Kineret®) or placebo (saline). The hypothesis is that anti-IL-1 treatment as
add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.
Objectives:
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the
feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining
or enhancing beta-cell function in people with new onset Type 1 diabetes.
Trial Design:
A randomized, placebo controlled, double masked, parallel group, multicentre trial of IL-1
antagonism in subjects with newly-diagnosed Type 1 diabetes. Patients are instructed to
inject 100 mg human recombinant interleukin-1 receptor antagonist (anakinra, Kineret®,
Amgen, CA) or placebo s.c. once daily for 2 years. Endpoints will be evaluated every three
months, with an interim analysis after 6 months.
Trial population:
The design will be a two-stage phase 2a study to address feasibility, safety/tolerability
and potential efficacy. In the first phase 80 patients between 18 and 35 years of age with
new on-set Type 1 diabetes will be randomized to anakinra or placebo, and endpoints will be
analyzed as an interim analysis after 6 months by an independent data and safety monitoring
board (DSMB). A futility analysis will be performed at this time point to prevent
continuation of the trial if it shows no likelihood of demonstrating efficacy. In the event
the trial does show promise of efficacy considering the power of the first phase based on a
conditional analysis the DSMB can recommend prolongation of the study with recruitment to
ensure adequate power, and that additional funding is provided.
Methods and interventions:
The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human
non-glycosylated interleukin-1 receptor antagonist (anakinra) at a dose of 100 mg once daily
or placebo by subcutaneous injection at the same time-point in the morning. Primary and
secondary endpoints and safety parameters are investigated after 1 month and then every 3
months.
Safety:
Anakinra is FDA approved for the indication rheumatoid arthritis and has an acceptable risk
/ benefit profile in this indication, with more than 100.000 patients treated. Most common
ad-verse events include mild and transient local injection reactions in 20-50% of subjects
treated with Anakinra. Consistent with its mechanism of action, anakinra reduces WBC/ANC in
2.4% of patients and this may increase the risk of infection. Accordingly, treatment with
anakinra will not be initiated in patients with active infections. Safety will be monitored
by physical exams and blood and urine tests.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |